Medication info

Hyubika HCT Tablet 5/40/12.5 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
(Co., Ltd.) Hyubist Pharmaceutical
Appearance
Light yellow round film-coated tablet
Packaging
30 tablets/PTP [(10 tablets/Alu-Alu × 3)]
Approval status
Expired

MFDS item code 201906516 · Approved 2019.09.18

This product's status changed to Expired on 2024.09.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with combination therapy of amlodipine and olmesartan
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration diagram. (The strengths of the individual ingredients are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use caution when administering to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with this medicine in patients 75 years and older, monitor them very carefully during treatment.
Child dose
The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Ingredients

Manufacturer
(Co., Ltd.) Hyubist Pharmaceutical

Efficacy & effects

Treatment of essential hypertension not controlled with combination therapy of amlodipine and olmesartan

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension when blood pressure control is inadequate with the combination of amlodipine and olmesartan medoxomil. This drug helps manage blood pressure by dilating blood vessels and lowering blood pressure. It contributes to reducing the risk of cardiovascular complications and improves overall health status. Therefore, it is a suitable treatment for patients who have difficulty controlling blood pressure due to essential hypertension.

How to take

Adult dose

Take 1 tablet once daily with water, with or without food. It is recommended to take it at the same time each day (e.g., in the morning), if possible. Before administering this medicine, it is recommended that the dose be adjusted using the individual ingredients (olmesartan medoxomil and amlodipine as monotherapy or combination therapy). However, if blood pressure is not controlled with the combination of amlodipine and olmesartan medoxomil as described below, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40/25mg of amlodipine/olmesartan medoxomil/hydrochlorothiazide. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/20mg. - 5/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 5/40mg or with this medicine 5/20/12.5mg. - 5/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/12.5mg. - 10/40/12.5mg: Administer to patients whose blood pressure is not adequately controlled with combination therapy of amlodipine/olmesartan medoxomil 10/40mg or with this medicine 5/40/12.5mg. - 10/40/25mg: Administer to patients whose blood pressure is not adequately controlled with this medicine 5/40/25mg or this medicine 10/40/12.5mg. ※ Refer to the following dose titration diagram. (The strengths of the individual ingredients are listed in the order of amlodipine/olmesartan medoxomil/hydrochlorothiazide.) 5/20/0mg → 5/20/12.5mg ↓ 5/40/0mg → 5/40/12.5mg → 5/40/25mg ↓ ↓ 10/40/0mg → 10/40/12.5mg → 10/40/25mg Patients with renal impairment The maximum dose of this medicine for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20/5/12.5 milligrams once daily. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. This medicine should not be administered to patients with severe renal impairment (creatinine clearance < 30mL/min). Patients with hepatic impairment Use caution when administering to patients with mild to moderate hepatic impairment. The maximum dose of this medicine for patients with moderate hepatic impairment is 5/20/12.5 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment. This medicine should not be administered to patients with severe hepatic impairment. Elderly patients (65 years and older) Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients. Since there is very limited experience with this medicine in patients 75 years and older, monitor them very carefully during treatment.

Child dose

The safety and efficacy of this medicine in pediatric patients under 18 years of age have not been established; therefore, its use is not recommended.

Precautions

This medication can cause serious harm to the fetus during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be used in patients with allergies to this drug or its ingredients, those with certain heart, kidney, or liver diseases, pregnant or nursing women, and patients with certain electrolyte imbalances. Patients with low blood volume or low salt may experience hypotensive symptoms when starting this medication, requiring careful monitoring and appropriate action if necessary. Patients with impaired kidney function, kidney transplant recipients, patients with renovascular hypertension, or those with liver function impairment require cautious observation and attention when using this medication. Because this drug has a strong blood pressure-lowering effect, elderly individuals or those with cardiovascular diseases should take extra care, as dizziness or lightheadedness may occur, and they should avoid dangerous machinery or driving. This medication may interact with various drugs, so it is important to consult with a physician or pharmacist if taking other medications. Regular blood tests to monitor electrolytes and kidney function are important during treatment with this medication. Nursing mothers are advised to avoid using this medication; if it is unavoidable, breastfeeding should be discontinued or the medication should be stopped. The safety and efficacy of this drug in children under 18 years of age have not been established, so its use is not recommended. In case of overdose, symptoms such as hypotension and palpitations may occur, and immediate medical attention should be sought for appropriate treatment. This medication should be stored away from direct sunlight and moisture, in a tightly sealed container, and should not be transferred to another container.

Side effects

Peripheral edema, headache, dizziness, upper respiratory infection, nasopharyngitis, urinary tract infection, sialadenitis, leukopenia, thrombocytopenia, bone marrow suppression, neutropenia, agranulocytosis, hemolytic anemia, aplastic anemia, anaphylactic reaction, drug hypersensitivity, hyperkalemia, hypokalemia, anorexia, diabetes, hypercalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypochloremia, hypertriglyceridemia, hypercholesterolemia, hyperuricemia, hypochloremic alkalosis, hyperamylasemia, confusion, depression, apathy, hypersensitivity, anxiety, mood changes, sleep disturbances, neurological abnormalities, orthostatic dizziness, syncope, taste disturbance, hypertonia, sensory decrease, paresthesia, peripheral neuropathy, drowsiness, syncope, convulsions, loss of appetite, tremors, visual disturbances, decreased tear production, worsening myopia, jaundice, vertigo, tinnitus, palpitations, tachycardia, myocardial infarction, arrhythmia, angina, hypotension, flushing, orthostatic hypotension, vasculitis, thrombosis, embolism, cough, bronchitis, dyspnea, pharyngitis, rhinitis, acute interstitial pneumonia, respiratory distress syndrome, pulmonary edema, diarrhea, nausea, constipation, dry mouth, abdominal pain, changes in bowel habits, abdominal distension, dyspepsia, gastritis, gastric discomfort, gastroenteritis, gingival hyperplasia, paralytic ileus, pancreatitis, vomiting, hepatitis, jaundice, acute cholecystitis, hair loss, angioedema, allergic dermatitis, erythema multiforme, erythema, lupus erythematosus-like skin reaction, pustular rash, exfoliative dermatitis, hyperhidrosis, photosensitive reaction, pruritus, purpura, angioedema, rash, recurrent lupus erythematosus, toxic skin necrosis, Stevens-Johnson syndrome, urticaria, muscle spasms, joint swelling, muscle weakness, ankle swelling, arthralgia, arthritis, low back pain, paresis, myalgia, bone pain, urinary frequency, acute kidney failure, hematuria, voiding dysfunction, nocturia, interstitial nephritis, renal failure, erectile dysfunction, gynecomastia, asthenia, fatigue, chest pain, fever, influenza-like symptoms, lethargy, malaise, edema, pain, facial swelling, elevated serum creatinine, elevated blood urea, elevated serum uric acid, decreased potassium levels, elevated gamma-glutamyl transferase, elevated alanine aminotransferase, elevated aspartate aminotransferase, elevated liver enzymes, elevated serum creatine phosphokinase, weight loss, weight gain, rhabdomyolysis, chronic malabsorption syndrome, altered consciousness, eczema, limb pain, mild decrease in average hemoglobin and hematocrit levels, acute respiratory distress syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This helps to maintain the drug's efficacy.

Appearance and packaging

Appearance

Light yellow round film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/Alu-Alu × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.